

1 **Behavioral and Magnetoencephalographic Correlates of Fear**
2 **Generalization Are Associated with Responses to Later Virtual Reality**
3 **Exposure Therapy in Spider Phobia**

4 **Short Title:** Fear Generalization is Associated with Later VRET-Response

5
6 Kati Roesmann, PhD^{1, 2}, Elisabeth Johanna Leehr, PhD³, Joscha Böhnlein, M.Sc.³, Christian
7 Steinberg, PhD¹, Fabian Seeger, M.Sc.⁴, Hanna Schwarzmeier, M.Sc.⁴, Bettina Gathmann,
8 PhD⁵, Niklas Siminski, M.Sc.⁴, Martin J. Herrmann, PhD⁴, Udo Dannlowski, PhD³, Ulrike
9 Lueken, PhD^{4,6}, Tim Klucken, PhD², Kevin Hilbert, PhD⁶, Thomas Straube, PhD² & Markus
10 Junghöfer, PhD¹

11
12 ¹ Institute for Biomagnetism and Biosignalanalysis, University of Münster, Germany

13 ² Institute for Clinical Psychology, University of Siegen, Germany

14 ³ Department of Psychiatry and Psychotherapy, University of Münster, Albert Schweitzer-
15 Campus 1, G 9A, 48149 Münster, Germany

16 ⁴ Center for Mental Health, Department of Psychiatry, Psychosomatics, and Psychotherapy,
17 University Hospital of Würzburg, Germany

18 ⁵ Institute of Medical Psychology and Systems Neuroscience, University of Münster, Germany

19 ⁶ Department of Psychology, Humboldt-Universität zu Berlin, Germany

20
21 **Corresponding Author:**

22 Kati Roesmann

23 University of Siegen

24 Institute for Clinical Psychology

25 Adolf-Reichwein-Str. 2a, Room AR NB 123

26 57076 Siegen, Germany

27 Phone: +49 271 740-5123

28 Email: Kati.Roesmann@uni-siegen.de

29 Word Count: 4211 words

30 Abstract: 231 words

31 Main Text: 3979 words

32 References: 40

33 Number of Tables: 1

34 Number of Figures: 4

35 Number of supplemental Tables: 4

36 Number of Supplemental Figures: 7

37 **Keywords:** Fear generalization, treatment outcome, exposure therapy, MEG/EEG, inhibitory
38 learning

39 **Abstract**

40 As overgeneralization of fear is a pathogenic marker of anxiety disorders, we investigated
41 whether pre-treatment levels of fear generalization in spider-phobic patients are associated with
42 their response to exposure-based treatment, in order to identify pre-treatment correlates of
43 treatment success. Ninety patients with spider phobia completed pre-treatment clinical and
44 magnetoencephalography (MEG) assessments, one session of virtual reality exposure therapy,
45 and a post-treatment clinical assessment. Based on the primary outcome (30% symptom
46 reduction in self-reported symptoms from pre- to post-treatment) they were categorized as
47 responders or non-responders. In a pre-treatment MEG fear generalization paradigm involving
48 fear conditioning with two unconditioned stimuli (UCS), we obtained fear ratings, UCS-
49 expectancy ratings, and event-related fields to conditioned stimuli (CS+, CS-) and 7 different
50 generalization stimuli (GS) on a perceptual continuum from CS+ to CS-. Prior to treatment,
51 non-responders showed behavioral overgeneralization indicated by more linear generalization
52 gradients in fear ratings. Analyses of MEG source estimations revealed that non-responders
53 showed a decline of their (inhibitory) frontal activations to safety-signaling CS- and GS
54 compared to CS+ over time, while responders maintained these activations at early (<300ms)
55 and late processing stages. Results provide initial evidence that pre-treatment differences of
56 behavioral and neural markers of fear generalization are associated with later responses to
57 behavioral exposure. Findings demonstrate the relevance of inhibitory learning functions and
58 their spatio-temporal neural reflections in this interplay. Findings stimulate research on
59 mechanism-based augmentation strategies for behavioral therapies.

60

1. Introduction

61 The first-line treatment for anxiety disorders is exposure-based cognitive-behavioral therapy
62 [1]. Yet, not all patients benefit equally. Non-response rates of up to 50% [2] have stimulated
63 research on factors that moderate treatment outcomes [3]. Despite considerable heterogeneity
64 of study approaches and findings, most identified factors are in line with the inhibitory learning
65 framework of exposure therapy (ET) [4]. This model assumes that ET does not erase the fear-
66 associated relations between phobic stimuli (conditioned stimuli, CS; e.g., a spider) and
67 expected aversive outcomes (unconditioned stimuli, UCS; e.g., a bite) – i.e., the CS/UCS traces.
68 Instead, it posits that ET produces new co-existing inhibitory CS/noUCS traces that connect the
69 CS with safety information [5, 6]. Thus, reductions of fear are expected if patients learn to
70 successfully discriminate between danger and safety signals and to inhibit fear responses in the
71 presence of safety cues [7].

72 Accordingly, one pre-treatment factor that might account for patients' variability in responses,
73 is the variance in inhibitory learning functions which can be investigated in classical
74 conditioning experiments. Aberrant processes during fear acquisition and extinction [8, 9], as
75 well as fear generalization [10–13] are considered promising pathogenic markers of anxiety
76 disorders. Fear generalization is defined as the transfer of conditioned fear responses to so-
77 called generalization stimuli (GS) that have never been paired with the UCS but that share
78 similarity with the threat-signaling CS+, such as orientation [14], size [10] or shape [15]. The
79 degree of fear generalization can be described by a generalization gradient along the relevant
80 dimension from the safety-signaling CS- via GS to the threat-signaling CS+.

81 Thereby, more fear generalization, or overgeneralization of fear, is indicated by linear (vs.
82 quadratic) and shallower gradients. Compared with healthy controls, this phenomenon has been
83 observed for patients with various anxiety disorders [10, 11, 16], but see [17]. Recent fear
84 conditioning studies have strengthened the hypothesis, that inhibitory learning mechanisms
85 contribute to the degree of fear generalization: For example, brain activity in frontal networks

86 that support fear inhibition [18] *decreases* as the GS approximates the threat-signaling CS+ [15,
87 19–21]. Such negative (“inhibitory”) gradients, which peak at or near the CS-, seem to be
88 modulated by pathological anxiety, with shallower negative generalization gradients in the
89 ventromedial prefrontal cortex (vmPFC) in generalized anxiety disorder [17]. Such failure to
90 recruit relevant brain networks supporting fear inhibition in the presence of safety cues likely
91 underpins anxiety-related overgeneralization (for review see [12]).

92 Negative generalization gradients have also been reported for the dorsolateral prefrontal cortex
93 (dlPFC), a region which also supports inhibitory processes during behavioral exposure [22].
94 Employing highly temporally resolving magnetoencephalography (MEG) which allows to
95 estimate underlying neural sources of event-related fields (ERF) with an acceptable spatial
96 resolution, we recently showed stronger “inhibitory” dlPFC activity evoked by GS that
97 resemble the safety signaling CS- [23]. These effects occurred at rather late time intervals
98 (>300ms), reflecting strategic emotion-regulation [24], but also already within the first 100ms
99 of stimulus processing.


100 Several studies have linked behavioral and neural pre-treatment correlates of fear acquisition
101 and extinction with treatment outcomes in ET [25–27]. However, such a relationship has not
102 been examined for fear generalization. Therefore, we here investigated whether pre-treatment
103 mechanisms of fear generalization are associated with later responses to ET. We hypothesized
104 that later non-responders versus responders would show pre-treatment overgeneralization in
105 their behavioral and neural (MEG) fear responses. On a neural level, non-responders’
106 overgeneralization should particularly be reflected in shallower negative frontal gradients. To
107 delineate temporal characteristics of associations between generalization gradients and
108 treatment-response to ET, we separately tested early (<300ms) and late stages (>300ms) of
109 processing within anterior neural networks. Predictions were tested in a sample of spider phobic
110 patients, who underwent a well-controlled virtual reality exposure therapy (VRET) [28].

111

2. Methods and Materials

112 2.1 Participants

113 Ninety patients with spider phobia according to the structured clinical interview for DSM-IV
114 [29] completed pre-treatment clinical and magnetoencephalography (MEG) assessments, one
115 session of virtual reality exposure therapy, and a post-treatment clinical assessment (Figure 1).
116 Patients were aged between 18 and 65 years, of Caucasian decent, right-handed and fluent in
117 German (Table 1). This study was approved by the Ethics Committee of the Medical Faculty
118 of the University of Münster. Patients consented to participate in all assessments and were
119 compensated with 180€ For more details, see SM1.1.



121 [Figure 1]

122 [Table 1]

123

124 **2.2 Material**

125 **2.2.1 Clinical Assessment of Treatment-Response**

126 We employed percentual reductions from the clinical pre- to post-treatment assessment in the
127 Spider Phobia Questionnaire (SPQ [30], registered as primary outcome at Clinical Trials.gov
128 (NCT03208400) to determine categorical treatment-response (TR-cat, responders vs. non-
129 responders) and dimensional outcomes (TR-dim). Responders were characterized by SPQ-
130 reductions of >30%, i.e. a clinically meaningful response (see [28]).

131 **2.2.2 Behavioral and MEG Assessment on Fear generalization**

132 Conditioned Stimuli and Generalization Stimuli (CS and GS)

133 Four sets of sinusoidal grating stimuli, each consisting of 9 stimuli, served as CS and GS. The
134 two most different stimuli in each set differed by 24° in their tilt angles and were used as CS+
135 and CS- (orientations: 11°/35°, 101°/125°, 56°/80°, and 146°/170°). Seven additional GS
136 ranged in steps of 3° between each CS+ and CS- pair. The assignment of CS+/CS- orientations
137 was balanced.

138 Unconditioned Stimuli (UCS)

139 A picture of a spider and a picture of a threatened female face [31] were selected as phobia-
140 related and phobia-unrelated UCS. Two auditory stimuli (a female scream [32] and a white
141 noise; 60 dB above individual hearing threshold) were presented simultaneously with the visual
142 stimuli, in counterbalanced combinations across participants and blocks (see Figure 2a). To
143 match physical characteristics the white noise was multiplied with the scream's temporally
144 inverted amplitude curve. Fear ratings were higher for phobia-related compared to phobia-
145 unrelated UCS and did not differ between responders and non-responders (see SM2.2.1).


146 **2.3 Procedure**

147 Patients first underwent a clinical pre-treatment assessment, which included primary and
148 secondary outcome measures, demographic and psychometric questionnaires, followed by the
149 behavioral and MEG assessment on fear generalization (+13.03 days, SD=9.38), the VRET
150 (+27.46 days, SD=10.35), and the clinical post-treatment assessment (+M=32.70, SD=12.02,
151 see Figure 1, for details see [28] and SM1.2-1.2.2). During VRET, patients were exposed to
152 virtual spiders in up to five different scenarios. The duration of behavioral exposure
153 ($t(87)=1.247$, $p=.216$, $M = 77.69$ min, $SD = 22.79$) and the experienced immersion in the virtual
154 environment measured by the Igroup Presence Questionnaire (IPQ, [33]) did not differ between
155 responders and non-responders (p 's in all subscales $>.16$, General Presence [0;6]: $M=4.91$,
156 $SD=0.95$], Spatial Presence [0;30]: $M=20.74$, $SD=12.63$; Involvement [0;24]: $M=13.60$,
157 $SD=11.84$, Experienced Realism [0;24]: $M=12.31$, $SD=3.71$).

158 **2.3.1 Behavioral and MEG Assessment on Fear generalization**

159 The experiment consisted of two similar blocks that differed only in randomization and in the
160 presented *UCS-type* (phobia-related and phobia-unrelated as with-in subject factor). Each block
161 consisted of a Baseline-MEG phase, a Conditioning-MEG phase that ended with a fear rating
162 of CS+, CS- and the respective UCS, and a Test-MEG phase that ended with fear- and UCS
163 expectancy ratings of all CS+, CS- and GSs. In a subsample, pupil dilation to CS and GS was
164 recorded in parallel with ERFs. In a Baseline and Test Perceptual Midpoint (PM) task before
165 and after MEG assessments (see Figure 2A and B) participants indicated whether GSs were
166 perceptually more similar to the CS+ or the CS-. Results revealed that discrimination abilities
167 and perceived perceptual midpoints of GSs were not modulated by phase (baseline vs. test), by
168 treatment-response or by interactions of these factors (see SM1.2.3. and SM2.2.3)

169



170

171

[Figure 2]

172

173 In each phase of MEG- (and pupil) recordings (see Figure 2, paradigm based on [20]), CS+,

174 CS-, and the 7 GSs (in baseline and test phases only) were presented consecutively in the center

175 of the screen for 800ms with a random inter-stimulus-interval of 1550-2150ms. Participants

176 kept their attention on the presented stimuli while behavioral reactions were not required.

177 In the Baseline- and Test-phases, all CS+, CS- and GS were presented 21 times each in
178 pseudorandomized order. At baseline, we recorded responses to all 9 *stimulus-types* (within-
179 subject factor) *before* they were contingently associated with the UCS. Additionally, the
180 respective UCS (phobia-related or unrelated) was presented seven times and was – as instructed
181 – always preceded by a warning sign (square or triangle, contingency rate: 100%) to achieve
182 constant arousal levels across baseline- and test-phases (21). In the conditioning-phase, CS+
183 and CS- stimuli were presented 60 times each in pseudorandomized order, whereby the UCS
184 (known from the baseline phase) replaced 33% of CS+. Patients were instructed that one grating
185 with a specific orientation was UCS predictive. Patients then rated the level of fear elicited by
186 the CSs and UCSs by button press on a ten-step numeric rating scale ranging from “no fear” to
187 “extreme fear” (i.e. fear ratings; instruction: “How much fear does this grating elicit?”). In the
188 subsequent Test-phase, responses to all *stimulus-types after* conditioning were assessed. CS+
189 continued to predict by the UCS (contingency rate: 33%, 7 UCS presentations) to prevent
190 extinction [34]. Again patients were fully instructed beforehand. Finally, behavioral fear- and
191 UCS-expectancy of CS+, CS-, and GS (three repetitions per stimulus; pseudorandomized order)
192 ratings were obtained. For UCS-expectancy ratings, patients estimated the probability the
193 visually presented *stimulus-type* predicted the UCS on a ten-step numeric rating scale (“very
194 unlikely” to “very likely”; instruction: “How likely was it, that this grating was followed by a
195 spider/face?”).

196 **2.3.2 Recording and Pre-processing of MEG Data**

197 ERFs were recorded and pre-processed as described in our previous MEG study on fear
198 generalization [23]. The spatiotemporal signal to different stimulus-types was computed
199 separately for each participant, block and phase. To increase the number of trials per category
200 and thus the signal-to-noise ratio, we merged ERFs in reaction to neighboring gratings (i.e.,
201 moving average) as previously applied [10]. Cortical sources underlying the averaged ERFs
202 were estimated using the L2-Minimum-Norm-Estimates (L2-MNE) method [23].

203 To avoid statistical artifacts due to potential outliers, patients were excluded if the mean of the
204 standard deviation across time between experimental conditions (N=6) or the mean number of
205 residual trials across experimental conditions (N=0) differed from the sample median by more
206 than four standard deviations. For visualization purposes, L2-MNE topographies were
207 projected on standard 3D brain models.

208 **2.4 Analysis**

209 To test the hypothesis that pre-treatment generalization gradients are related to the later
210 *treatment-response*, we specifically explored interactions of *treatment-response* with linear and
211 quadratic contrasts in the factor *stimulus-type* and *stimulus-type* by *UCS-type* interactions using
212 mixed-measures ANOVAs (for TR-cat) and ANCOVAS (for TR-dim). Analyses were run
213 separately for fear and UCS-expectancy ratings (obtained in the test-phase), and estimated
214 neural activity (L2MNE). Additionally, fear ratings of CS and UCS (obtained post-
215 conditioning) were analysed using ANOVAS. Clinical and behavioral data were analyzed using
216 the programs R (2015) and SPSS 24 (IBM Corp., Armonk, NY) with a significance level of
217 $\alpha=.05$.

218 To focus on gradients specifically induced by the conditioning procedure and to extract purely
219 perceptual effects elicited by the different tilt angles of the stimuli, all statistical MEG analyses
220 were based on difference topographies (Test minus Baseline). First, we aimed to identify
221 spatiotemporal clusters reflecting linear generalization effects observed in the fear and UCS-
222 expectancy ratings of responders and non-responders. Thus, linear contrasts with the factor
223 *stimulus-type* across groups were calculated for each time point and dipole. Identified clusters
224 that additionally revealed treatment-outcome-dependent (TR-cat and TR-dim) modulations of
225 gradients (Bonferroni-corrected for the number of clusters) are presented in the main text.
226 Second, to directly identify clusters displaying differential generalization of responders and
227 non-responders, difference topographies were investigated in a *stimulus-type* by *treatment-*

228 *response* interaction analysis, in which orthogonal linear contrasts [17] were calculated for each
229 time point and dipole¹.

230 To correct for multiple comparisons within the predefined time intervals (IOI: 0-300ms, 300-
231 600ms) and anterior region of interest (ROI), we adopted a non-parametrical statistical testing
232 procedure [35] as used previously [23] to determine significant spatiotemporal clusters. Details
233 on recording, preprocessing and analyses of MEG and pupil responses as well as supplementary
234 analyses on dimensional outcomes and individual response prediction are presented in SM
235 1.2.4-7.

236 3. Results

237 3.1 Clinical effect of VRET

238 SPQ-reductions from pre- to post-treatment assessment ($t(88)=20.59$, $p<.001$, $d=2.18$, $M_{Pre} =$
239 22.61 , $SD_{Pre} = 2.00$; $M_{Post} = 15.54$, $SD_{Post} = 3.02$) supported the expectation of a highly effective
240 VRET (for clinical effects, see also [36] and SM2.1). According to our primary outcome
241 criterion (30% SPQ-reduction [28]), 48.31% of all patients responded to VRET (SPQ-
242 reductions of 42.06% in responders and 20.66% in non-responders). SPQ-responders were also
243 characterized by stronger percentual pre-to-post reductions of avoidance in the BAT than non-
244 responders ($t(87)=2.140$, $p=.035$). Importantly, responders and non-responders did not differ in
245 primary (SPQ) and secondary (BAT) outcome measures before therapy (for details see Table
246 1).


¹ As behavioral *stimulus-type* by *treatment-response* interactions did not depend on *UCS-type*, this dependency was not tested via permutation analyses on a neural level.

247 **3.2 Fear Ratings and UCS-Expectancy Ratings**

248 Post-conditioning, but before the test phase, we revealed different fear ratings of CS+ and CS-
249 and a modulation of this differentiation by *UCS-type*, while CS+, CS- and UCS fear ratings did
250 not differ between responders and non-responders (see SM2.2.1).

251 After the test phase, we observed a significant linear ($F(1,87)=146.704, p<.001, \eta^2=.628$) and a
252 quadratic ($F(1,87)=3.984, p=.049, \eta^2=.044$) main effect for *stimulus-type*, with flattened
253 gradients for GS showing increasing similarity with the CS- (see Figure 3, top). As predicted,
254 we found a significant interaction of *stimulus-type* by *treatment-response*, which was evident
255 for the quadratic ($F(1,87)=5.046, p=.027, \eta^2=.055$) but not for the linear gradient
256 ($F(1,87)=0.014, p=.906, \eta^2=.000$) and independent of *UCS-type* ($F(1,87)=0.836, p=.363,$
257 $\eta^2=.010$). Post-hoc analyses for each group revealed quadratic gradients in responders
258 ($F(1,42)=7.317, p=.010, \eta^2=.148$) but not in non-responders ($F(1,45)=0.039, p=.844, \eta^2=.001$).

259 UCS-expectancy ratings also showed significant linear ($F(1,87)=288.441, p<.001, \eta^2=.768$) and
260 quadratic ($F(1,87)=32.498, p<.001, \eta^2=.272$) main effects of *stimulus-type*. However, UCS-
261 expectancy ratings did not differ between responders and non-responders (linear:
262 $F(1,87)=0.652, p=.421, \eta^2=.007$; quadratic: ($F(1,87)=0.199, p=.657, \eta^2=.002$, see Figure 3,
263 bottom). The three-way interaction *stimulus-type* by *treatment-response* by *UCS-type* was not
264 significant (linear: $F(1,87)=0.121, p=.729, \eta^2=.001$; quadratic: $F(1,87)=0.561, p=.456,$
265 $\eta^2=.006$). Associations between treatment-response and quadratic gradients in the factor
266 *stimulus-type* of fear ratings could be confirmed in the MEG-sample for both TR-cat and TR-
267 dim (see SM2.2.2, Table S2). Pupil responses revealed the expected linear positive gradients
268 which were, however, not modulated by *treatment-response* (see SM2.3).




269

270

[Figure 3]

271 **3.3 MEG data**



272

273

[Figure 4]

274 3.3.1 Negative “inhibitory” anterior linear contrasts

275 Overall four anterior clusters that were characterized by a negative gradient peaking at the
276 safety-signaling CS-² yielded significance (see SM2.4.1., Figure S2). One left dlPFC cluster
277 (Figure 4A, 110-157ms after stimulus onset, p -cluster=0.003) additionally yielded a significant
278 interaction of *stimulus-type* by *treatment-response* ($F(1,68)=9.351$, $p=.003$, $p_{\text{corrected}}=.012$, η^2
279 $=.121$) that was qualified by a distinct negative linear gradient in responders ($F(1,35)=26.830$,
280 $p<.001$, $\eta^2=.434$) but not in non-responders ($F(1,33)=1.900$, $p=.177$, $\eta^2=.054$). Again,
281 treatment-response-dependent gradients were not modulated by *UCS-type* ($F(1,68)=1.205$,
282 $p=.276$, $\eta^2=.017$). Convergent to the categorical analysis, linear gradients in this cluster were
283 also associated with TR-dim ($F(1,68) = 6.616$, $p = .012$, $p_{\text{corrected}}=.048$, $\eta^2 = 0.089$, Table S3).
284 TR-dim was additionally associated with the quadratic gradient in a cluster in right ventrolateral
285 prefrontal regions that extended to the right TPJ (210-300ms, $F(1,68) = 7.499$, $p = .008$, $p_{\text{corrected}}$
286 $= .032$, $\eta^2=.099$). Specifically, larger percentual reductions of SPQ-scores were associated with
287 stronger negative quadratic gradients. This pattern resulted from overall stronger brain
288 responses to the CS- and GS compared to the CS+ (see Figure S4). Negative linear contrasts at
289 late latencies or positive linear contrasts were non-significant in anterior regions.

290 3.3.2 Orthogonal linear contrasts

291 Orthogonal linear contrasts (a complementary analysis directly testing for associations of linear
292 gradients and *treatment-response* (TR-cat) without necessity of negative gradients across
293 groups) revealed two additional clusters at rather late latencies (see Figure 4B).

294 In a left dorso- and ventrolateral prefrontal cluster (505–557ms, p -cluster=.025), responders
295 showed a marginal negative gradient ($F(1,35)=3.907$, $p=.056$, $\eta^2=.100$) while non-responders
296 revealed a significant positive gradient ($F(1,33)=10.698$, $p=.003$, $\eta^2=.245$). Similar effects were
297 observed in a cluster spanning areas of the right anterior temporal pole and ventral orbitofrontal

² Negative ‘Test minus Base’ differences indicate relatively reduced neural responses to stimuli from Test to Base. We here interpret the relative trend observed in these differences.

298 cortex (427–493ms, p -cluster=.013) where responders again revealed negative
299 ($F(1,35)=11.937$, $p=.001$, $\eta^2=.254$) but non-responders positive gradients ($F(1,33)=7.993$,
300 $p=.008$, $\eta^2=.195$). Again, effects within both clusters were not modulated by the *UCS-type*
301 ($F_s < 1$). Supplemental analyses based on the dimensional treatment outcome (TR-dim,
302 SM2.4.3-4) further confirmed these results. First, ANCOVAS within the two orthogonal
303 clusters revealed that linear gradients in both clusters were also significantly associated with
304 TR-dim (Table S4). Second, cluster permutation analyses on associations between individual
305 linear polynomial parameters (per dipole and timepoint) and TR-dim in the anterior ROI were
306 performed. These regression analyses yielded one cluster in bilateral anterior temporal areas and
307 large areas of orbital and vmPFC (Figure S5) that covered areas of cluster Ant-Int-2 and
308 supported the link between stronger “inhibitory” frontal negative gradients and symptom
309 reductions. This analysis yielded no clusters in left dlPFC/vlPFC.

310 **3.4 Prediction of individual responses to treatment – an exploratory machine learning** 311 **approach**

312 With a supplemental machine learning analysis, we estimated the potential of individual
313 generalization gradients as predictors for individual treatment-responses (TR-cat), rather than
314 a group-level correlate thereof [37]. Our prediction model, which included linear and quadratic
315 polynomial coefficients of fear and expectancy ratings, and of neural activity in clusters
316 revealing linear gradients as features, revealed a mean balanced prediction accuracy of 58.6%
317 ($p = .076$, SM2.5).

318 **4. Discussion**

319 We aimed to test the hypothesis that pre-treatment mechanisms of fear generalization in anxiety
320 patients and related inhibitory neural mechanisms in PFC regions are associated with later
321 treatment outcomes to behavioral exposure therapy. We found that spider-phobic patients who
322 did not respond to later VRET showed an overgeneralization in their behavioral fear ratings as

323 well as diminished inhibitory or even inverted gradients in frontal brain networks compared to
324 treatment-responders. These findings are in line with current models of inhibitory learning as a
325 core mechanism for the development, maintenance and treatment of anxiety disorders. They
326 furthermore show that pre-treatment configurations in brain networks conferring fear
327 generalization are related with treatment-response, thus potentially opening up new avenues for
328 personalized treatment augmentation (e.g. degeneralization trainings).

329 Both groups showed the expected linear gradients in fear ratings, but responders only
330 additionally followed a quadratic trend indicative of less generalization. This finding suggests
331 that deficits of fear generalization in later non-responders compared to responders resemble
332 aberrant fear generalization of anxiety-disordered patients compared to healthy controls [10,
333 11]. Importantly, responders and non-responders did not differ regarding their baseline fear
334 levels or further potential confounds like evaluations of CS and UCS (SM2.2.1), perceptual
335 aspects of fear conditioning assessed in the PM task (SM1.3.3), relevant psychometric variables
336 or treatment characteristics like duration of exposure or experience of immersion. Further,
337 effects were specific for fear ratings and not evident in UCS expectancies or pupil dilation³.
338 The dissociations of fear- and expectancy ratings suggest that affective, rather than cognitive
339 aspects [34] of fear generalization are linked with treatment success.

340 As predicted, negative linear gradients were observed in dorso- and ventrolateral prefrontal
341 networks [23] and revealed relatively stronger reactions to safety-signaling CS- and GS (vs.
342 CS+) in responders. This replication of early-onset negative gradients in dorsolateral prefrontal
343 regions [23] further emphasizes that “inhibitory” frontal structures – amongst other functions –
344 modulate early, presumably more implicit aspects of fear generalization. Importantly, the early
345 left-hemispheric dlPFC negative gradients were driven by the later treatment-responders, while

³ Please find a discussion on the lack of effects in pupil dilation data, collected in a subsample of patients, in the supplementary materials (SM2.3)

346 non-responders revealed no inhibition of safety cues. A convergent, even more pronounced
347 interaction was found in left-lateralized dlPFC/vlPFC in a later time interval (505–557ms).
348 Correspondingly, dimensional treatment outcomes were associated with linear polynomial
349 parameters in all of these left dlPFC/vlPFC clusters, and with quadratic parameters in the right
350 vlPFC. Overall, this pattern suggests that responders maintained inhibitory frontal activations
351 to safety-signaling CS- and GS compared to CS+ across time, while non-responders failed to
352 do so. In combination with the behavioral evidence for overgeneralization of fear in non-
353 responders, this observation supports previous speculations that overgeneralization might be
354 mediated by aberrant dlPFC recruitment [38]. Importantly, the dlPFC supports regulatory
355 processes, which are needed to differentiate relevant stimuli and to overcome anxiety in the
356 presence of safety [38]. In line with this, influential models of emotion regulation converge in
357 the notion of inhibitory top-down influences of lateral prefrontal structures on neural systems
358 involved in emotion generation (e.g. amygdala, [18]) and perception (see SM2.4.5). Linking
359 negative frontal generalization gradients with treatment-response to VRET, our study provides
360 initial support for the hypothesis that inhibitory learning during exposure therapy [4, 22] and
361 during fear generalization are mediated by at least overlapping regulatory brain systems. The
362 finding of fast, emotional correlates of inhibitory deficiencies in non-responders suggests that
363 implicit affective processes might be a promising target for therapeutic augmentation strategies
364 (e.g. degeneralization training), and might complement cognitive and context-based strategies
365 suggested in inhibitory learning models [4].

366 Yet, several aspects require consideration: First, the categorical analysis of treatment response
367 did not reveal the predicted generalization gradients and/or differences of gradients between
368 responders and non-responders in the vmPFC, which has often been associated with fear-
369 inhibition during safety learning [15, 19–21] and overgeneralization of fear in anxiety disorders
370 [12, 17]. However, supplemental dimensional analyses in fact revealed an increasingly
371 improved treatment outcome with increasingly negative “inhibitory” gradients at anterior

372 temporal/ventral orbitofrontal effects (Figure 4) extending to the adjacent vmPFC (Figure S5).
373 Nevertheless, given the limited MEG sensor coverage of the vmPFC and a lower resolution of
374 the MEG (vs. MRI) for deeper sources, particularly the observed vmPFC effects require
375 replication using more sensitive modalities.

376 Second, negative gradients were not only observed in the predicted frontal regions, but also in
377 anterior and posterior temporal brain regions, which have been linked to processes of
378 perception, attention and recognition rather than fear inhibition (see SM2.4.2-5, Figures S2,
379 S6). In line, a systematic review on neural predictive markers for treatment-response identified
380 a consistent contribution of the temporal lobe across studies [39]. Thus, the functional interplay
381 between temporal and frontal structures in treatment-response and generalization should be
382 delineated by future research.

383 Third, via our variance-analytic approach – opposed to a *genuine predictive* machine learning
384 approach [37] – *group-level associations* between pre-treatment fear generalization and later
385 treatment-response were established. Our supplemental *predictive* approach demonstrates that
386 behavioral and magnetoencephalographic markers of fear generalization might also hold
387 valuable information for the *prediction* of individual exposure outcomes. Yet, prediction
388 models in new, larger and independent samples are needed to estimate the clinical utility of fear
389 generalization.

390 Noteworthy, we observed no evidence for an influence of the *UCS-type* on behavioral and
391 neural gradient differentiations between responders and non-responders suggesting that general
392 rather than domain-specific fear generalization mechanisms are associated with treatment-
393 responses in spider phobia. This finding seems to contrast with previous evidence for domain-
394 specific conditioning effects in spider phobia [40]. However, while UCS ratings of responding
395 and non-responding patients did not differ here, UCS ratings strongly differed between patients

396 and controls [40]. Thus, the subjective UCS aversiveness should be considered in future studies
397 on the domain-specificity of pathological learning processes in anxiety patients.

398 To conclude, this study provides initial evidence that pre-treatment differences of behavioral
399 and neural markers of fear generalization are associated with later responses to behavioral
400 exposure. Particularly patients who did not profit from later VRET showed overgeneralized
401 fear responses and aberrant neural generalization effects. Our findings support the relevance of
402 inhibitory learning functions in frontal brain networks during fear generalization and suggest
403 that their spatio-temporal neural reflections underpin the interplay of fear generalization in the
404 laboratory and responses to exposure therapy (ET). These insights may stimulate the
405 development of mechanism-based augmentation strategies for ET. Future investigations on the
406 value of individual fear generalization patterns as predictive markers for treatment outcomes
407 may help to identify anxiety patients who may not profit from ET. This may enable researchers
408 and clinicians to personalize and thereby optimize treatment strategies for this vulnerable
409 patient group [39].

410

Acknowledgement

411 We would like to thank Tilman Coers, Julia Wandschura, Marielle Clerc, Hannah Casper, Sarah
412 Hein, Karin Wilken, Andreas Wollbrink, Ute Trompeter, and Hildegard Deitermann (Institute
413 for Biomagnetism and Biosignalanalysis), Tina Jocham, Jana Scharnagl, and Inge Gröbner
414 (Dept. of Psychiatry, University Hospital of Würzburg); Dominik Grotegerd, Ramona
415 Lennings, Manuel Kraft, Merle Gebauer, Sarah Thissen, Elena Wilkens, Jonathan Repple, Nina
416 Muck, Stella Fingas, Janina Werner, Anna Kraus, and Kordula Vorspohl (Dept. of Psychiatry,
417 University of Münster); Harald Kugel, Jochen Bauer, and Birgit Vahrenkamp (Dept. of Clinical
418 Radiology, University of Münster), Lea Borgmann, Jaqueline Brieke, Aylin Fuchs, Carolin
419 Heinemann, Annika Hense, Valeria Kleinitz, Kaja Loock, Johannes Lücke, and Kathrin Rüb
420 (Institute of Medical Psychology and Systems Neuroscience), for their help and support.

421 **Statement of Ethics**

422 This research complies with the guidelines for human studies and was conducted ethically in
423 accordance with the World Medical Association Declaration of Helsinki.

424 **Disclosure Statement**

425 The authors have no conflicts of interest to declare.

426 **Funding Sources**

427 This work was funded by the German Research Foundation (DFG) – project number 44541416
428 (CRC-TRR 58: Project C08 to MJ and TS, Project C09 to UD and UL, Project C07 to TS and
429 MJH) and the “Innovative Medizinische Forschung” (IMF) of the medical faculty of Münster
430 (grant number RO211907 to KR).

431 **Author Contributions**

432 KR, TS & MJ conceptualized and designed the work. KR, ELJ, JB, FS, HS, MJH, UD & UL
433 conceptualized and implemented the VRET. KR, KH & MJ analyzed and interpreted the data.
434 KR drafted the work. All authors revised it critically, approved the manuscript to be published
435 and agreed to be accountable for all aspects of the work in ensuring that questions related to the
436 accuracy or integrity of any part of the work are appropriately investigated and resolved.

437 **References**

- 438 [1] Bandelow B, Wiltink J, Alpers GW, et al. Deutsche S3-Leitlinie Behandlung von
439 Angststörungen.
- 440 [2] Loerinc AG, Meuret AE, Twohig MP, et al. Response rates for CBT for anxiety
441 disorders: Need for standardized criteria. *Clin Psychol Rev* 2015; 42: 72–82.
- 442 [3] Böhnlein J, Altegoer L, Muck NK, et al. Factors influencing the success of exposure
443 therapy for specific phobia: A systematic review. *Neuroscience and Biobehavioral*
444 *Reviews* 2020; 108: 796–820.
- 445 [4] Craske MG, Liao B, Brown L, et al. Role of Inhibition in Exposure Therapy. *J Exp*

- 446 *Psychopathol* 2012; 3: 322–345.
- 447 [5] Bouton ME, Moody EW. Memory processes in classical conditioning. In:
448 *Neuroscience and Biobehavioral Reviews*. Pergamon, 2004, pp. 663–674.
- 449 [6] Lonsdorf TB, Merz CJ. More than just noise: Inter-individual differences in fear
450 acquisition, extinction and return of fear in humans - Biological, experiential,
451 temperamental factors, and methodological pitfalls. *Neuroscience and Biobehavioral*
452 *Reviews* 2017; 80: 703–728.
- 453 [7] Jovanovic T, Kazama A, Bachevalier J, et al. Impaired safety signal learning may be a
454 biomarker of PTSD. *Neuropharmacology* 2012; 62: 695–704.
- 455 [8] Lissek S, Powers AS, McClure EB, et al. Classical fear conditioning in the anxiety
456 disorders: a meta-analysis. *Behav Res Ther* 2005; 43: 1391–1424.
- 457 [9] Duits P, Cath DC, Lissek S, et al. Updated meta-analysis of classical fear conditioning
458 in the anxiety disorders. *Depress Anxiety* 2015; 32: 239–253.
- 459 [10] Lissek S, Rabin S, Randi HE, et al. Overgeneralization of Conditioned Fear as a
460 Pathogenic Marker of Panic Disorder. *Am J Psychiatry* 2010; 167: 47–55.
- 461 [11] Lissek S, Kaczkurkin AN, Rabin S, et al. Generalized anxiety disorder is associated
462 with overgeneralization of classically conditioned fear. *Biol Psychiatry* 2014; 75: 909–
463 915.
- 464 [12] Dunsmoor JE, Paz R. Fear Generalization and Anxiety: Behavioral and Neural
465 Mechanisms. *Biol Psychiatry* 2015; 78: 336–343.
- 466 [13] Dymond S, Dunsmoor JE, Vervliet B, et al. Fear Generalization in Humans: Systematic
467 Review and Implications for Anxiety Disorder Research. *Behav Ther* 2015; 46: 561–
468 582.
- 469 [14] McTeague LM, Gruss LF, Keil A. Aversive learning shapes neuronal orientation
470 tuning in human visual cortex. *Nat Commun* 2015; 6: 7823.
- 471 [15] Greenberg T, Carlson JM, Cha J, et al. Neural reactivity tracks fear generalization
472 gradients. *Biol Psychol* 2013; 92: 2–8.
- 473 [16] Dymond S, Schlund MW, Roche B, et al. The spread of fear: Symbolic generalization
474 mediates graded threat-avoidance in specific phobia. *Q J Exp Psychol* 2014; 67: 247–
475 259.
- 476 [17] Greenberg T, Carlson JM, Cha J, et al. Ventromedial prefrontal cortex reactivity is
477 altered in generalized anxiety disorder during fear generalization. *Depress Anxiety*
478 2013; 30: 242–50.
- 479 [18] Hartley CA, Phelps EA. Changing fear: The neurocircuitry of emotion regulation.
480 *Neuropsychopharmacology* 2010; 35: 136–146.
- 481 [19] Dunsmoor JE, Prince SE, Murty VP, et al. Neurobehavioral mechanisms of human fear
482 generalization. *Neuroimage* 2011; 55: 1878–1888.
- 483 [20] Onat S, Büchel C. The neuronal basis of fear generalization in humans. *Nat Neurosci*
484 2015; 18: 1811–1818.
- 485 [21] Lissek S, Bradford DE, Alvarez RP, et al. Neural substrates of classically conditioned
486 fear-generalization in humans: A parametric fMRI study. *Soc Cogn Affect Neurosci*

- 487 2014; 9: 1134–1142.
- 488 [22] Landowska A, Roberts D, Eachus P, et al. Within- and between-session prefrontal
489 cortex response to virtual reality exposure therapy for acrophobia. *Front Hum*
490 *Neurosci*; 12. Epub ahead of print 1 November 2018. DOI:
491 10.3389/fnhum.2018.00362.
- 492 [23] Roesmann K, Wiens N, Winker C, et al. Fear generalization of implicit conditioned
493 facial features – Behavioral and magnetoencephalographic correlates. *Neuroimage*
494 2020; 205: 116302.
- 495 [24] Hajcak G, Nieuwenhuis S. Reappraisal modulates the electrocortical response to
496 unpleasant pictures. *Cogn Affect Behav Neurosci* 2006; 6: 291–297.
- 497 [25] Ball TM, Knapp SE, Paulus MP, et al. Brain activation during fear extinction predicts
498 exposure success. *Depress Anxiety* 2017; 34: 257–266.
- 499 [26] Lange I, Goossens L, Michielse S, et al. Neural responses during extinction learning
500 predict exposure therapy outcome in phobia: results from a randomized-controlled trial.
501 *Neuropsychopharmacology* 2020; 45: 534–541.
- 502 [27] Waters AM, Pine DS. Evaluating differences in Pavlovian fear acquisition and
503 extinction as predictors of outcome from cognitive behavioural therapy for anxious
504 children. *J Child Psychol Psychiatry Allied Discip* 2016; 57: 869–876.
- 505 [28] Schwarzmeier H, Leehr EJ, Böhnlein J, et al. Theranostic markers for personalized
506 therapy of spider phobia: Methods of a bicentric external cross-validation machine
507 learning approach. *Int J Methods Psychiatr Res*. Epub ahead of print 8 December 2019.
508 DOI: 10.1002/mpr.1812.
- 509 [29] Wittchen H-U, Wunderlich U, Gruschwitz S, et al. SKID I. Strukturiertes Klinisches
510 Interview für DSM-IV. Achse I: Psychische Störungen. Interviewheft und
511 Beurteilungsheft. Eine deutschsprachige, erweiterte Bearbeitung der amerikanischen
512 Originalversion des SKID I.
- 513 [30] Rinck M, Bundschuh S, Engler S, et al. Reliability and validity of German versions of
514 three instruments measuring fear of spiders. *Diagnostica; Informationsorgan Über*
515 *Psychol Tests und Untersuchungsmethoden* 2002; 48: 141–149.
- 516 [31] Tottenham N, Tanaka JW, Leon AC, et al. The NimStim set of facial expressions:
517 judgments from untrained research participants. *Psychiatry Res* 2009; 168: 242–9.
- 518 [32] Bradley MM, Lang PJ. International affective digitized sounds (IADS): Stimuli,
519 instruction manual and affective ratings (Tech. Rep. No. B-2).
- 520 [33] Schubert TW. The sense of presence in virtual environments: A three-component scale
521 measuring spatial presence, involvement, and realness. *Zeitschrift für Medien* 2003; 15:
522 69–71.
- 523 [34] Lonsdorf TB, Menz MM, Andreatta M, et al. Don't fear 'fear conditioning':
524 Methodological considerations for the design and analysis of studies on human fear
525 acquisition, extinction, and return of fear. *Neurosci Biobehav Rev* 2017; 77: 247–285.
- 526 [35] Maris E, Oostenveld R. Nonparametric statistical testing of EEG- and MEG-data. *J*
527 *Neurosci Methods* 2007; 164: 177–190.
- 528 [36] Leehr EJ, Roesmann K, Böhnlein J, et al. Clinical predictors of treatment response
529 towards exposure therapy in virtual reality in spider phobia: a machine learning and external

- 530 cross-validation approach. *J Anxiety Disord.*
- 531 [37] Poldrack RA, Huckins G, Varoquaux G. Establishment of Best Practices for Evidence
532 for Prediction: A Review. *JAMA Psychiatry* 2020; 77: 534–540.
- 533 [38] Balderston NL, Hsiung A, Ernst M, et al. Effect of threat on right dlPFC activity during
534 behavioral pattern separation. *J Neurosci* 2017; 37: 9160–9171.
- 535 [39] Lueken U, Zierhut KC, Hahn T, et al. Neurobiological markers predicting treatment
536 response in anxiety disorders: A systematic review and implications for clinical
537 application. *Neuroscience and Biobehavioral Reviews* 2016; 66: 143–162.
- 538 [40] Schweckendiek J, Klucken T, Merz CJ, et al. Weaving the (neuronal) web: Fear
539 learning in spider phobia. *Neuroimage* 2011; 54: 681–688.

540

541

Figure Legends

542 **Figure 1:** Flow-chart visualizing the recruitment pathway of the clinical sample described here.

543 100 eligible patients completed behavioral and magnetoencephalographic assessments on fear
544 generalization. Out of these, 92 patients completed the virtual reality exposure therapy (VRET)
545 and 90 completed the clinical post-treatment assessment. One of these patients was excluded
546 from the behavioral and the MEG-analysis, because one part of the generalization paradigm
547 was not completed. Another 19 patients were excluded from the MEG-analyses due to
548 insufficient data quality in any MEG acquisition (preprocessing criterion: N=13, outlier
549 analysis: N=6). Note that this study was embedded in a joint prospective longitudinal project
550 of the Transregional Collaborative Research Center “Fear, Anxiety, Anxiety Disorders” (CRC-
551 TRR58 funded by the German Research Foundation) employing VRET as a first-line treatment
552 for specific phobia and pre-defined response criteria (for details, see supplemental materials:
553 SM1).

554

555 **Figure 2:** Experimental Procedure for the Behavioral and MEG Assessment on Fear
556 generalization. A) Overview on the procedure, consisting of an informatory block and two
557 experimental blocks that resembled each other except for randomization and the applied *UCS-*
558 *type* (phobia-related vs phobia-unrelated). The order of blocks was counterbalanced across

559 patients. B) Each block consisted of a Baseline Perceptual Midpoint (PM) Task, an MEG-
560 Baseline phase, an MEG-Conditioning phase which terminated with a fear rating of the CS+,
561 the CS- and the respective audiovisual USs, an MEG-Test-Phase, which terminated with fear-
562 and UCS expectancy ratings of the CS+, the CS- and all GS, and – again – the PM Task. C)
563 Sequence of stimulus presentation during the MEG baseline, conditioning and test phase in a
564 phobia-related block. Stimuli were repeatedly presented. In the Conditioning and Test phase
565 the CS+ predicted the US (here: phobia related) in 33% of the cases while a warning signal
566 predicted all US in the baseline phase. Parallel to the MEG-signal pupil dilation was recorded.
567 D) Example of stimuli used as CS and GS (here: set A, orientations between 11° and 35°).

568

569 **Figure 3:** Results of fear and UCS-expectancy ratings. Linear (black line) and quadratic (blue
570 line) behavioral generalization effects in fear rating and in UCS-expectancy ratings (N=89) are
571 indicated. Fear ratings revealed overgeneralization in non-responders as indexed by a missing
572 quadratic gradient in this group, i.e. a significant interaction in quadratic gradients. UCS-
573 expectancy ratings revealed equivalent quadratic and linear gradients in both groups. Note that
574 fear ratings and UCS-expectancy ratings revealed qualitatively similar results in the MEG
575 sample of N=70 patients (see Table S2).

576

577 **Figure 4:** Significant spatiotemporal clusters showing differential generalization gradients for
578 responders and non-responders in the anterior region of interest (Ant). (A) Cluster Ant-Neg 1
579 revealed a significant “inhibitory” gradient in the permutation test (Neg, indicated in blue) at
580 early latencies. Importantly, while responders showed stronger brain activations to
581 generalization stimuli resembling the safety-signaling CS-, non-responders showed no
582 differentiation. (B) Significant spatiotemporal clusters revealing interaction effects (Int) in
583 linear gradients, i.e. orthogonal contrasts (indicated in black), were revealed for the late time
584 interval only. Both clusters revealed negative linear gradients for responders, while non-

FEAR GENERALIZATION IS ASSOCIATES WITH LATER VRET-RESPONSE 27

585 responders revealed the opposite pattern. The observed clusters spatially overlap with regions
586 showing main effects in the early time interval (Figure S2).

587 Bar graphs show the regional neural activity (Test minus Base in nAM) in the displayed
588 clusters. Error bars denote 95% confidence intervals.

FEAR GENERALIZATION MODERATES LATER VRET-RESPONSE

1 **Table 1: Demographic and clinical characteristics of treatment responders and non-responders before and after VRET for the MEG**
 2 **sample (N = 70).**
 3

Characteristic	Responders #		Non-Responders ##		Test t [χ^2]	df	p
	M	SD	M	SD			
Primary Response Criterion							
(Reduction in SPQ [%])	>= 30		< 30%				
Sample size [N, %]	43/89	48.31	46	51.69			
Reduction in SPQ [%, SD]	42.06	8.41	20.66	6.78	13.258	87	<.001***
Demographic Characteristics							
Female gender [N, %]	35	81.4	36	78.3	$\chi^2 = 1.35$	1	.713
Age (years)	26.07	7.81	28.85	9.24	1.527	87	.130
Years of education	14.91	2.57	14.91	2.89	0.007	86	.994
Clinical Characteristics							
Age of onset (years)	5.76	4.45	6.73	5.15	0.590	86	.557
Comorbid major depression [N, %]	3	7.0	1	2.2			
Comorbid subordinate animal phobia [N, %]	1	2.3	1	2.2			
SPQ pre	22.95	2.03	22.28	1.93	1.697	87	.114
SPQ post	13.26	2.00	17.67	2.12	10.09	87	<.001***
BAT (final distance in cm) pre	173.71	76.91	171.97	75.11	0.108	87	.914
BAT (final distance in cm) post	78.38	67.32	98.40	70.62	1.367	87	.175
Reduction in BAT [%, SD]	56.04	32.35	41.65	31.08	2.140	87	.035*
CGI pre [N, %]					$\chi^2 = 2.717$	3	.437
Mildly ill	4	9.3	6	13.0			

Characteristic	Responders #		Non-Responders ##		Test		
	M	SD	M	SD	t [χ^2]	df	p
Moderately ill	24	55.8	18	39.1			
Markedly ill	15	34.9	19	41.3			
Severely ill	0	0.0	1	2.2			
CGI post [N, %]					$\chi^2 = 6.615$	4	.158
Not ill	2	4.7	1	2.2			
Marginally ill	5	11.6	2	4.3			
Mildly ill	24	55.8	20	43.5			
Moderately ill	9	20.9	21	45.7			
Markedly ill	2	4.7	2	4.3			
Severely ill	0	0.0	0	0.0			
STAI trait pre	35.58	9.69	36.022	8.21	0.231	86	.818
BDI-II total pre	3.70	4.74	3.58	3.95	0.129	86	.898
BDI-II total post	4.05	5.75	3.07	3.34	0.990	86	.325
UI-18: total pre	41.16	13.51	39.11	12.52	0.739	86	.462
UI-18: total post	42.05	13.42	41.63	12.97	0.148	86	.883

4 *Note.* Means, standard deviations, t-values (M, SD, t; except where noted), degrees of freedom (df) and significance level (p, two-sided) for each characteristic;
5 SPQ, Spider Phobia Questionnaire; BAT, behavioral avoidance test; CGI, Clinical Global Impression; STAI-Trait, trait-version of the State-Trait Anxiety Inventory;
6 BDI-II, Beck Depression Inventory-II; UI-18, Intolerance of Uncertainty Scale – 18. # Missing values for responders: Age of onset (1), CGI rating post (1), BDI
7 post (1), Ui-18: total post (1); Imputed data for non-responders (0) ## Missing values for non-responders: Years of education (1), CGI rating pre (2), STAI pre (1),
8 BDI pre (1), UI-18: total pre (1); Imputed data for non-responders: BAT pre (1), BAT post (1). Characteristics of the MEG sample (N=70) as well as references
9 of the employed psychometric questionnaires are presented in Table S1.